Form 4: Enliven Therapeutics Director, Lori Anne Kunkel, Reports Stock Option Grant

Director Lori Anne Kunkel reports the acquisition of stock options in Enliven Therapeutics, Inc.

Summary

• Lori Anne Kunkel, a director of Enliven Therapeutics, Inc. (ELVN), filed a Form 4 on February 10, 2025, reporting a transaction.
• On February 6, 2025, Kunkel acquired stock options to purchase 15,368 shares of Enliven Therapeutics common stock at an exercise price of $22.47 per share.
• These options vest on the earlier of the first anniversary of the 2025 annual meeting or the date of the 2026 annual meeting, contingent upon Kunkel's continued service as a non-employee director.
• The options expire on February 6, 2035.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing related to stock option grants, which is neither particularly positive nor negative.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing them to work towards the company's success.

Industry Context

Stock options are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotechnology and pharmaceutical industries, to align their interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for directors in publicly traded companies, especially in the biotech sector.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize stock options as part of their director compensation to incentivize performance and align interests with shareholders.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially leading to decisions that benefit the company's long-term value.

Key Dates

Keywords

Form 4, stock options, director, Enliven Therapeutics, ELVN, beneficial ownership, Lori Anne Kunkel